SWOG clinical trial number
SWOG-8814

Phase lll Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors (Intergroup)

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
Phase lll Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive…
Activated
05/15/1989
Closed
08/01/1995

Research committees

Breast Cancer

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2016

The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814

W Woodward;W Barlow;R Jagsi;T Buccholz;S Shak;F Baehner;C Yoshizawa;T Whelan;N Davidson;J Ingle;T King;P Ravdin;C Osborne;D Tripathy;R Livingston;J Gralow;G Hortobagyi;D Hayes;K Albain Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S146;oral; ASTRO Annal Meeting (September 25 - 28, 2016, Boston, MA)

Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)

H Pan;R Gray;C Davies;J Bergh;K Pritchard;M Dowsett;DF Hayes Journal of Clinical Oncology 34, 2016 (suppl; abstr 505); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

K Albain;M Crager;W Barlow;F Baehner;A Bergamaschi;JM Rae;P Ravdin;D Tripathy;J Gralow;RB Livingston;CK Osborne;JN Ingle;K Pritchard;NE Davidson;LA Carey;DB Cherbavaz;AP Sing;G Hortobagyi;DF Hayes San Antonio Breast Cancer Symposium (Dec 6-10, 2016, San Antonio, TX), poster discussion, #PD7-07

2015

Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – transcriptome expression analysis of the phase III trial SWOG-8814

K Albain;M Crager;WE Barlow;F Baehner;A Bergamaschi;J Rae;P Ravdin;D Tripathy;G Gralow;R Livingston;CK Osborne;JN Ingle;K Pritchard;NE Davidson;LA Carey;D Cherbavaz;AP Sing;AP Shak;G Hortobagyi;DF Hayes San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abst.# P5-07-01;

Successful whole transcriptome analysis of 25-year-old samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies

D Cherbavaz;D Hayes;K Qu;MR Crager;WE Barlow;A Goddard;EM Beasley;J Jeong;F Collin;M-L Liu;J Rae;P Ravdin;D Tripathy;J Gralow;R Livingston;CK Osborne;JN Ingle;K Pritchard;NE Davidson;LA Carey;AP Sing;F Baehner;G Hortobagyi;S Shak;K Albain San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), poster, abst.# P5-07-01;

2014

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2012

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

R Peto;C Davies;J Godwin;R Gray;H Pan;M Clarke;D Cutter;S Darby;P McGale;C Taylor;YC Yang;J Bergh;A DiLeo;K Albain;S Swain;M Piccart;K Pritchard Lancet 379(9814):432-444

PMid: PMID22152853 | PMC number: PMC3273723

2010

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [PMID20005174; PMC3058239]

K Albain;W Barlow;S Shak;GN Hortobagyi;RB Livingston;IT Yeh;PM Ravdin;R Bugarini;F Baehner;N Davidson;G Sledge;E Winer;C Hudis;J Ingle;E Perez;K Pritchard;L Shepherd;JR Gralow;C Yoshizawa;DC Allred;CK Osborne;DF Hayes Lancet Oncology 11:55-65

Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials

S Albain;W Barlow;S Shak;G Hortobagyi;D Hayes Journal of Clinical Oncology 28:72s(suppl; abstr 511); oral

In the interest of full disclosure - author's reply [correspondence] [PMID20359663]

K Albain;W Barlow Lancet Oncology 11(4):315

2009

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node positive breast cancer: a phase 3 open-label, randomised controlled trial [PMID20004966; PMC3140679]

KS Albain;SJ Green;PM Ravdin;WB Farrar;GV Burton;SJ Ketchel;CD Cobau;EG Levine;JN Ingle;KI Pritchard;AS Lichter;DJ Schneider;MD Abeloff;IC Henderson;L Norton;D Lew;WE Barlow;RB Livingston;S Martino;CK Osborne Lancet 374(9707):2055-2063

Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]

D Hershman;J Unger;W Barlow;L Hutchins;S Martino;CK Osborne;RB Livinsgton;KS Albain Journal of Clinical Oncology 27(13):2157-2162

Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene recurrence score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)

K Albain;W Barlow;SA Shak;G Hortobagyi;R Livingston;IT Yeh;P Ravdin;R Bugarini;B Baehner;NE Davidson;G Sledge;W Winer;C Hudis;J Ingle;EA Perez;K Pritchard;L Shepherd;J Gralow;C Yoshizawa;D Allred;C Osborne;D Hayes San Antonio Breast Cancer Symposium, abst. 112, poster discussion presentation

2007

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-negative, ER-positive breast cancer (S8814, INT0100)

K Albain;W Barlow;S Shak;G Hortobagyi;R Livingston;I Yeh;P Ravdin;C Yoshizawa;F Baehner;N Davidson;G Sledge;E Winer;C Hudis;J Ingle;E Perez;K Pritchard;L Shepherd;C Allred;K Osborne;D Hayes San Antonio Breast Cancer Symposium #10

2006

Outcome of African American women with breast cancer in cooperative group clinical trials

JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands

Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897

D Hershman;J Unger;W Barlow;L Hutchins;S Martino;M Abeloff;L Norton;R Livingston;CK Osborne;K Albain San Antonio Breast Cancer Symposium Proceedings #3049

2004

Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814)

K Albain;W Barlow;F O'Malley;K Siziopikou;IT Yeh;P Ravdin;D Lew;W Farrar;G Burton;S Ketchel;C Cobau;E Levine;J Ingle;K Pritchard;A Lichter;D Schneider;M Abeloff;IC Henderson;L Norton;D Hayes;S Green;R Livingston;S Martino;CK Osborne;DC Allred SABCS, late acceptance:#37, http://www.abstracts2view.com/sabcs/sessionindex.php

2002

Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814).

KS Albain;SJ Green;PM Ravdin;CD Cobau;EG Levine;JN Ingle;KI Pritchard;DJ Schneider;MD Abeloff;L Norton;IC Henderson;D Lew;RB Livingston;S Martino;CK Osborne Proc of the American Society of Clinical Oncology 21:37a(#143)

2001

Overall survival after cyclophosphamide, adriamycin, 5-Fu, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup trial S8814 (INT-0100)

K Albain;S Green;P Ravdin;C Cobau;E Levine;J Ingle;K Pritchard;D Schneider;M Abeloff;L Norton;D Lew;S Martino;CK Osborne Proc of the American Society of Clinical Oncology 20:24a(#94)

1997

Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100).

K Albain;S Green;K Osborne;C Cobau;E Levine;J Ingle;K Pritchard;D Schneider;J O'Sullivan;E Hess;S Martino Proc of the American Society of Clinical Oncology 16:128a(#450)

1996

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.

KS Albain;SR Green;AS Lichter;LF Hutchins;WC Wood;IC Henderson;JN Ingle;J O'Sullivan;CK Osborne;S Martino Journal of Clinical Oncology 14(11):3009-3017

1994

The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.

A Lichter;S Green;K Albain;L Hutchins;S Martino ASCO 13:62(#51)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7436

Combined Modality Therapy of Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
01/09/1975
Closed
07/18/1979
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
07/16/1979
Closed
08/01/1989
Accrual
100%
Closed
Phase
III
Published